Wave Life Sciences CMO Michael Panzara resigns; Anne-Marie Li-Kwai-Cheung promoted to CDO

Wave Life Sciences Ltd.

Michael Panzara, M.D., MPH, resigns as CMO effective Oct 14, 2022, to pursue another opportunity; no disagreement with company.
Dr. Panzara will serve as consultant post-resignation for transition.
Anne-Marie Li-Kwai-Cheung promoted to Chief Development Officer effective Oct 14, 2022.
Li-Kwai-Cheung previously led Roche's tominersen Phase 3 program and Ocrevus global launch.
She brings deep neurology and rare disease drug development experience to Wave.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Panzara

Chief Medical Officer, Head of Therapeutics Discovery and Development

WVE · Wave Life Sciences Ltd.

Effective: 2022-10-14
Successor: Anne-Marie Li-Kwai-Cheung
Filed: September 26, 2022, 7:59 PM ET

On September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development of Wave Life Sciences Ltd. (the “Company”), resigned effective as of October 14, 2022 to pursue another opportunity.

Appointed

Anne-Marie Li-Kwai-Cheung

Chief Development Officer

WVE · Wave Life Sciences Ltd.

Effective: 2022-10-14
Filed: September 26, 2022, 7:59 PM ET

Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheung will be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Panzara resigned as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences Ltd..

Action: resigned
Role: Chief Medical Officer, Head of Therapeutics Discovery and Development

Exact text from the filing

On September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development of Wave Life Sciences Ltd. (the “Company”), resigned effective as of October 14, 2022 to pursue another opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Anne-Marie Li-Kwai-Cheung was appointed as Chief Development Officer at Wave Life Sciences Ltd..

Action: promoted
Role: Chief Development Officer

Exact text from the filing

Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheung will be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.

View on SEC.gov

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-22-251264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.